[1]Caldwell S, Argo C.The natural history of non-alcoholic fat-ty liver disease[J].Dig Dis, 2010, 28 (1) :162-168.
|
[2]Bellentani S, Scaglioni F, Marino M, et al.Epidemiology ofnon-alcoholic fatty liver disease[J].Dig Dis, 2010, 28 (1) :155-161.
|
[3]Fan JG, Farrell GC.Epidemiology of non-alcoholic fatty liverdisease in China[J].J Hepatol, 2009, 50 (1) :204-210.
|
[4]Adams LA, Lymp JF, St SJ, et al.The natural history ofnonalcoholic fatty liver disease:a population-based cohortstudy[J].Gastroenterology, 2005, 129 (1) :113-121.
|
[5]黄欣, 张哲永.当飞利肝宁胶囊治疗非酒精性脂肪性肝病32例临床观察[J].中医杂志, 2007, 48 (6) :524-525.
|
[6]张雳.当飞利肝宁胶囊治疗脂肪肝257例临床观察[J].中医杂志, 2005, 46 (4) :276.
|
[7]吴佳玉, 江南, 黄仁刚.当飞利肝宁治疗非酒精性脂肪性肝炎的临床研究[J].四川省卫生管理干部学院学报, 2008, 27 (3) :192-193.
|
[8]武敬, 彭雁忠.当飞利肝宁胶囊对酒精性脂肪肝患者疗效分析[J].医学信息 (中旬刊) , 2010, 5 (5) :1252.
|
[9]丁葆英.当飞利肝宁胶囊治疗慢性乙型肝炎45例[J].中医杂志, 2009, 50 (4) :367.
|
[10]宋毅, 刘培曦.当飞利肝宁防治抗结核药致肝损害的效果观察[J].中国现代药物应用, 2011, 5 (3) :13-14.
|
[11]Kucera O, Lotkova H, Stankova P, et al.Is rat liver affectedby non-alcoholic steatosis more susceptible to the acutetoxic effect of thioacetamide?[J].Int J Exp Pathol, 2011, 92 (4) :281-289.
|
[12]Donthamsetty S, Bhave VS, Mitra MS, et al.Nonalcoholicfatty liver sensitizes rats to carbon tetrachloride hepatotoxicity[J].Hepatology, 2007, 45 (2) :391-403.
|
[13]Lackner C.Hepatocellular ballooning in nonalcoholic steato-hepatitis:the pathologist's perspective[J].Expert Rev Gas-troenterol Hepatol, 2011, 5 (2) :223-231.
|
[14]周大成, 朴惠善, 秦文杰, 等.当药的研究进展[J].时珍国医国药, 2011, 22 (2) :462-465.
|
[15]周大成, 朴惠善, 张思玉, 等.当药提取物对鼠试验性肝损伤的保护作用[J].中国实验方剂学杂志, 2010, 16 (17) :125-128.
|
[16]王玉刚, 施敏, 陈锡美, 等.水飞蓟素治疗大鼠非酒精性脂肪性肝炎的机制探讨[J].中华消化杂志, 2008, 28 (4) :263-265.
|
[17]段钟平, 朱跃科, 陈煜, 等.水飞蓟宾磷脂复合物防治脂肪肝的动物试验与临床观察[J].实用肝脏病杂志, 2008, 11 (4) :218-221.
|
[18]程勇, 苏剑, 田艳, 等.水飞蓟宾胶囊对非酒精性脂肪性肝病患者血清IL-8、TNFα的影响[J].山东医药, 2009, 49 (7) :62-63.
|
[19]陈黎, 陈枝俏.当飞利肝宁胶囊联合血脂康治疗合并高脂血症的非酒精性脂肪性肝病[J].中国中医药信息杂志, 2007, 14 (2) :64-65.
|
[20]刘芳, 谢贤春, 吉中和, 等.当飞利肝宁胶囊治疗高脂血症及脂肪肝的实验研究[J].医学理论与实践, 2007, 20 (3) :251-253.
|
[21]黄久荣, 梁若梅.当飞利肝宁胶囊在降脂治疗中的保肝作用观察[J].中医杂志, 2007, 48 (7) :598.
|
[22]Garcia-Monzon C, Lo IO, Mayoral R, et al.Hepatic insulinresistance is associated with increased apoptosis and fibro-genesis in nonalcoholic steatohepatitis and chronic hepatitis C[J].J Hepatol, 2011, 54 (1) :142-152.
|
[23]Ratziu V, Caldwell S, Neuschwander-Tetri BA.Therapeutictrials in nonalcoholic steatohepatitis:insulin sensitizers andrelated methodological issues[J].Hepatology, 2010, 52 (6) :2206-2215.
|
[24]杨玉锋, 南月敏.脂联素与非酒精性脂肪性肝病的研究进展[J].临床肝胆病杂志, 2009, 25 (2) :155-157.
|
[25]Polyzos SA, Kountouras J, Zavos C.The role of adiponectinin the pathogenesis and treatment of non-alcoholic fatty liv-er disease.[J].Diabetes Obes Metab, 2010, 12 (5) :365-383.
|
[26]Savvidou S HPOH.Low serum adiponectin levels are predic-tive of advanced hepatic fibrosis in patients with NAFLD[J].J Clin Gastroenterol, 2009, 43 (8) :765-772.
|
[27]Fukushima J, Kamada Y, Matsumoto H, et al.Adiponectinprevents progression of steatohepatitis in mice by regulatingoxidative stress and Kupffer cell phenotype polarization[J].Hepatol Res, 2009, 39 (7) :724-738.
|
[28]Tilg H.The role of cytokines in non-alcoholic fatty liver dis-ease[J].Dig Dis, 2010, 28 (1) :179-185.
|